Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 3/20 | 0.62 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | GSK3B | P49841 | 1/20 | 0.55 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.52 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.52 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.52 |
| ▸ | FYN | P06241 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | PRKDC | P78527 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ATR | Q13535 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18670976 | 0.81 | LDHA (0.56) | HDAC2HDAC1HDAC3GSK3BMAP4K4 | |
| SCHEMBL18670955 | 0.81 | GSK3B (0.55) | CHEK2MKNK1HDAC2HDAC1HDAC3 | |
| SCHEMBL18670971 | 0.80 | GSK3B (0.53) | HDAC2HDAC1HDAC3GSK3B | |
| SCHEMBL3646469 | 0.80 | HDAC1 (0.60) | HDAC2HDAC1HDAC3GSK3B | |
| SCHEMBL18670958 | 0.79 | HDAC1 (0.71) | HDAC2HDAC1HDAC3GSK3B | |
| SCHEMBL18670987 | 0.79 | HDAC1 (0.54) | HDAC2HDAC1HDAC3GSK3B | |
| SCHEMBL27810689 | 0.79 | HDAC1 (0.53) | HDAC2HDAC1HDAC3GSK3B | |
| SCHEMBL4620246 | 0.77 | CHEK2 (1.00) | CHEK2MKNK1FYNMAP4K4 | |
| SCHEMBL12077792 | 0.76 | CHEK2 (0.87) | CHEK2MKNK1FYNMAP4K4 | |
| SCHEMBL3777895 | 0.76 | HDAC1 (0.54) | HDAC2HDAC1HDAC3GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526090-B1 | NEW ANTI-MALARIAL AGENTS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2015-08-19 | — | — | EP | claimed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | claimed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | claimed |
| WO-2011086531-A2 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2011-07-21 | — | — | WO | claimed |
| EP-2526090-B1 | NEW ANTI-MALARIAL AGENTS | MEDICINES FOR MALARIA VENTURE MMV (CH) | 2015-08-19 | — | — | EP | disclosed |
| US-9024033-B2 | Anti-malarial agents | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2015-05-05 | — | — | US | disclosed |
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2012-11-22 | — | — | US | disclosed |
| WO-2011086531-A2 | NEW ANTI-MALARIAL AGENTS | MMV MEDICINES FOR MALARIA VENTURE (CH) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295905-A1 | NEW ANTI-MALARIAL AGENTS | QDPR, DHFR, ITPA | CHEK2 4817/4885MKNK1 2043/4885HDAC2 3082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.